Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 88.13% | 100.84% | 161.52% | 123.95% | -305.02% |
| Total Depreciation and Amortization | 6.88% | -2.61% | 1.27% | 3.76% | -15.67% |
| Total Amortization of Deferred Charges | 2.25% | 2.25% | 2.25% | 2.25% | 35.60% |
| Total Other Non-Cash Items | -83.65% | -97.53% | -126.11% | -103.83% | 899.26% |
| Change in Net Operating Assets | -1,026.22% | -1,307.94% | -2,070.03% | 32.82% | 93.84% |
| Cash from Operations | -34.26% | -52.96% | -85.98% | 0.97% | 113.20% |
| Capital Expenditure | 20.79% | 17.21% | -11.87% | -163.38% | 12.72% |
| Sale of Property, Plant, and Equipment | -93.68% | -93.68% | -93.51% | -91.76% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,083.28% | 206.87% | 429.12% | -35.97% | 90.62% |
| Cash from Investing | -1,503.38% | -286.87% | 407.25% | -45.95% | 90.11% |
| Total Debt Issued | 3,713.86% | 2,736.02% | 0.92% | -27.59% | -94.78% |
| Total Debt Repaid | -178.97% | -167.99% | 9.68% | 5.68% | -8.44% |
| Issuance of Common Stock | -22.36% | 78.39% | 187.85% | 163.68% | 141.06% |
| Repurchase of Common Stock | 62.71% | 63.61% | 71.51% | 83.39% | 46.96% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 18.73% | 27.04% | 28.39% | 22.82% | -30.35% |
| Cash from Financing | 145.97% | 143.49% | 52.22% | 59.39% | -204.48% |
| Foreign Exchange rate Adjustments | -60.26% | -3,045.88% | -14.13% | -41.54% | -76.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 286.41% | -33.40% | 579.22% | 267.10% | 84.95% |